Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
PD1/PD-L1
>>
Phase 3
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
33
66
99
132
165
198
231
264
297
330
Bavencio
(avelumab) / EMD Serono
Jemperli
(dostarlimab-gxly) / GSK
spartalizumab
(PDR001) / Novartis
bintrafusp alfa
(M7824) / EMD Serono
Zynyz
(retifanlimab-dlwr) / Incyte
balstilimab
(AGEN2034) / Agenus
retlirafusp alfa
(SHR-1701) / Jiangsu Hengrui Pharma
Pembroria
(pembrolizumab biosimilar) / Biocad
Yidafan
(ivonescimab) / Akesobio, Summit Therap
ezabenlimab
(BI 754091) / Boehringer Ingelheim
erfonrilimab
(KN046) / Alphamab
Opdualag
(nivolumab/relatlimab) / BMS, Ono Pharma
budigalimab
(ABBV-181) / AbbVie
Puyouheng
(pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med
favezelimab/pembrolizumab
(MK-4280A) / Merck (MSD)
volrustomig
(MEDI5752) / AstraZeneca
sasanlimab
(PF-06801591) / Pfizer
BNT327
/ BioNTech
cetrelimab
(JNJ-63723283) / J&J
iparomlimab/tuvonralimab
(PSB205) / Sound Biologics, Qilu Pharma
Cejemly
(sugemalimab) / CStone Pharma
vibostolimab/pembrolizumab
(MK-7684A) / Merck (MSD)
quavonlimab/pembrolizumab
(MK-1308A) / Merck (MSD)
rilvegostomig
(AZD2936) / AstraZeneca
socazolimab
(STI-A1014) / Sorrento
Forteca
(prolgolimab) / Biocad
nivolumab subcutaneous
(BMS-986298) / BMS, Ono Pharma
IO102-IO103
/ IO Biotech
rulonilimab
(F520) / Lunan Pharma
BAT1308
/ Bio-Thera Solutions
Enshuxing
(enlonstobart) / CSPC Pharma, Sumgen Biotech
tebotelimab
(MGD013) / MacroGenics
Tecentriq SC
(atezolizumab/hyaluronidase) / Roche
finotonlimab
(SCT-I10A) / Sinocelltech
iparomlimab
(QL1604) / Qilu Pharma
AM0001
/ Eli Lilly
nofazinlimab
(CS1003) / CStone Pharma
tagitanlimab
(HBM9167) / Harbour BioMed
pembrolizumab/hyaluronidase
(MK-3475A) / Merck (MSD)
cosibelimab
(CK-301) / TG Therap, Fortress
pembrolizumab subcutaneous
(MK-3475 SC) / Merck (MSD)
Nurdati
(prolgolimab/nurulimab) / Biocad
BA1104
(nivolumab biosimilar) / Luye Group
BGB-108
/ BeiGene
MB12
(pembrolizumab biosimilar) / Grupo Insud
